CC
VTYX

Callan Capital’s Ventyx Biosciences VTYX Stock Holding History

Callan Capital’s Portfolio VTYX Stock Details VTYX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-16,310
Closed -$35.6K – 372
2024
Q3 		$35.6K Hold
16,310
– – ﹤0.01% 348
2024
Q2 		$37.7K Hold
16,310
– – ﹤0.01% 314
2024
Q1 		$89.7K Hold
16,310
– – 0.01% 291
2023
Q4 		$40.3K Sell
16,310
-2,870
-15% -$27.3K ﹤0.01% 233
2023
Q3 		$666K Hold
19,180
– – 0.07% 98
2023
Q2 		$629K Hold
19,180
– – 0.07% 96
2023
Q1 		$643K Hold
19,180
– – 0.07% 94
2022
Q4 		$629K Buy
+19,180
New +$568K 0.08% 97

Other funds holding VTYX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
SCM
Sio Capital Management New York $604M AUM 96.57% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

Callan Capital's VTYX Position: Q4 2024 in Review

Callan Capital sold out of Ventyx Biosciences (VTYX) in Q4 2024, closing a stake of 16,310 shares — an estimated $35.6K sold.

Callan Capital first reported a position in VTYX in Q4 2022 and held it in 8 quarters. The position peaked at $666K in Q3 2023. 124 funds tracked by Wall St. Rank hold VTYX as of Q4 2024.

  • Callan Capital reported no remaining Ventyx Biosciences position as of Q4 2024 after selling out during the quarter.
  • Callan Capital sold 16,310 Ventyx Biosciences shares in Q4 2024, an estimated $35.6K.
  • Callan Capital first reported a position in Ventyx Biosciences in Q4 2022 and held it in 8 quarters.
  • Callan Capital's Ventyx Biosciences position peaked at $666K in Q3 2023.
  • 124 funds tracked by Wall St. Rank held Ventyx Biosciences as of Q4 2024.

Based on Callan Capital's 13F filing for Q4 2024, filed 3 Feb 2025.